{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:04:10Z","timestamp":1793930650903,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.semarthrit.2025.152891","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:17:03Z","timestamp":1765473423000},"page":"152891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-7069","authenticated-orcid":false,"given":"Koji","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8977","authenticated-orcid":false,"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0001-1078","authenticated-orcid":false,"given":"Kanako","family":"Shimanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8401-8044","authenticated-orcid":false,"given":"Hiroyuki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2025.152891_bib0001","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/art.42860","article-title":"2023 American college of rheumatology (ACR)\/American college of chest physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0002","article-title":"Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis","volume":"38","author":"Sebastiani","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00296-025-05854-y","article-title":"Radiological extent predicts prognosis and relapse after acute exacerbation of interstitial lung disease in patients with rheumatoid arthritis: kEIO-RA-cohort","volume":"45","author":"Suzuki","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0004","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/pc2kq1","article-title":"Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review","author":"Suzuki","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0005","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0006","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1164\/rccm.202205-0910LE","article-title":"Austin ILD Registry and CARE-PF Investigators. Patient characteristics and survival for progressive pulmonary fibrosis using different definitions","volume":"207","author":"Khor","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0008","article-title":"Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease","author":"Morrisroe","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0009","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/rheumatology\/kex077","article-title":"Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study","volume":"57","author":"Reiseter","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive decline of lung function in rheumatoid arthritis\u2013associated interstitial lung disease","volume":"69","author":"Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45027-0","article-title":"Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease","volume":"13","author":"Sakamoto","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0012","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0013","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial Lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0014","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152710","article-title":"Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients","volume":"72","author":"Atienza-Mateo","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0016","doi-asserted-by":"crossref","DOI":"10.63032\/POPM9413","article-title":"Antifibrotics in rheumatoid arthritis-associated interstitial lung disease - real-world data from a nationwide cohort","author":"Duarte","year":"2024","journal-title":"ARP Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152312","article-title":"Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease","volume":"64","author":"Juge","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13237074","article-title":"Real-world clinical effectiveness and safety of antifibrotics in progressive pulmonary fibrosis associated with rheumatoid arthritis","volume":"13","author":"Narv\u00e1ez","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0019","article-title":"Efficacy and safety of nintedanib in patients with connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): a real-world single center experience","volume":"13","author":"Boutel","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41927-024-00400-y","article-title":"Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study","volume":"8","author":"Ushio","year":"2024","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0021","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-025-07323-0","article-title":"Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: a multicenter retrospective study","author":"M\u0131s\u0131rc\u0131","year":"2025","journal-title":"Clin Rheumatol [Internet]"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0022","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11845-024-03848-6","article-title":"Nintedanib and its combination with immunosuppressives in connective tissue disease-related interstitial lung diseases","volume":"194","author":"Tekgoz","year":"2025","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0023","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0024","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0026","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0027","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14397595.2019.1709944","article-title":"2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0028","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for primary Sj\u00f6gren\u2019s Syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0029","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0031","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0032","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0033","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0034","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745233","article-title":"KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0037","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/art.21322","article-title":"Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia","volume":"53","author":"Kocheril","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0038","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1007\/s10238-023-01212-z","article-title":"Clinical effect of progressive pulmonary fibrosis on patients with connective tissue disease-associated interstitial lung disease: a single center retrospective cohort study","volume":"23","author":"Lee","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0039","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/resp.14231","article-title":"Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases","volume":"27","author":"Brown","year":"2022","journal-title":"Respirology"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0040","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0041","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01592-2016","article-title":"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry","volume":"49","author":"Jo","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and tolerability of Nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0043","article-title":"Functional progression after dose suspension or discontinuation of nintedanib in idiopathic pulmonary fibrosis: a real-life multicentre study","volume":"17","author":"Ruaro","year":"2024","journal-title":"Pharmaceuticals (Basel) [Internet]"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0044","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0045","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0046","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","article-title":"Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial","volume":"79","author":"Seibold","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0047","doi-asserted-by":"crossref","first-page":"A452","DOI":"10.1016\/j.chest.2017.08.479","article-title":"No effect of dose adjustments on long-term reduction in FVC decline with nintedanib in patients with idiopathic pulmonary fibrosis (IPF)","volume":"152","author":"Huggins","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0048","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/03009742.2024.2327159","article-title":"Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases","volume":"53","author":"Ayano","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152891_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107603","article-title":"Predictive factors for dose reduction and discontinuation of nintedanib in fibrotic interstitial lung diseases: real life data","volume":"225","author":"Costa","year":"2024","journal-title":"Respir Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:29:16Z","timestamp":1767850156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225002628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":49,"alternative-id":["S0049017225002628"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152891","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152891"}}